Virtue Capital Management’s Novartis NVS Stock Holding History

Virtue Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,681	Closed	-$207K	–	192
2018 Q3	$207K	Buy	+2,681	New	+$198K	0.04%	241
2018 Q2	–	Sell	-2,664	Closed	-$185K	–	376
2018 Q1	$185K	Buy	2,664 +146	+6%	+$11.1K	0.1%	191
2017 Q4	$189K	Buy	+2,518	New	+$190K	0.11%	172

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Virtue Capital Management's NVS Position: Q4 2018 in Review

Virtue Capital Management sold out of Novartis (NVS) in Q4 2018, closing a stake of 2,681 shares — an estimated $207K sold.

Virtue Capital Management first reported a position in NVS in Q4 2017 and held it in 3 quarters. The position peaked at $207K in Q3 2018. 1,087 funds tracked by Wall St. Rank hold NVS as of Q4 2018.

Virtue Capital Management reported no remaining Novartis position as of Q4 2018 after selling out during the quarter.
Virtue Capital Management sold 2,681 Novartis shares in Q4 2018, an estimated $207K.
Virtue Capital Management first reported a position in Novartis in Q4 2017 and held it in 3 quarters.
Virtue Capital Management's Novartis position peaked at $207K in Q3 2018.
1,087 funds tracked by Wall St. Rank held Novartis as of Q4 2018.

Based on Virtue Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.